Due to the uncertainty of how the Covid-19 pandemic will continue to impact global public health in the coming months, the Large Animal Genetic Engineering Summit is being postponed until June 6-9, 2021.
We are at work with the meeting venue, contacting our scheduled speakers, and will update information here when new dates are confirmed. People who were already registered for the summit will soon be contacted individually. The organizing committee wishes safety for our colleagues and friends around the world at this difficult time, as we all strive to continue making scientific advances.
Large Animal Genetic Engineering Summit
To Be Determined
Abstract Instructions and Submission
RESEARCH • APPLICATIONS • POLICY
Remarkable developments in genome editing are revolutionizing medicine and agriculture as large animal genomes can, for the first time, be modified with sophistication and efficiency so far only achievable in the mouse. This technology allows for improvement in livestock production traits, agricultural animal health and welfare, and generation of more refined large animal models for biomedical applications. The summit will bring together reproductive biologists, geneticists, molecular biologists, animal model developers, preclinical and clinical researchers, and representatives of federal research and regulatory agencies.
The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) will hold an animal biotechnology stakeholder outreach meeting immediately after the Large Animal Genetic Engineering Summit on June 17, 2020 from 3pm-6pm.
At this meeting, the CVM will collect feedback from stakeholders on its regulatory process for intentional genomic alterations (IGAs) in animals. The feedback will help the CVM to enhance the predictability, transparency, and efficiency of the IGA review process under the Veterinary Innovation Program (VIP). The VIP is available to most IGA developers and is aimed at facilitating advancements in the development of innovative animal products by providing greater certainty in the regulatory process, encouraging development and research, and supporting an efficient and predictable pathway to approval.
CVM representatives will elaborate on the science- and risk-based approach for IGAs, and will engage in an in-depth discussion about the organization’s risk analysis and review process, including case studies with information about the risk questions CVM poses for specific types of products. The session will conclude with a question and answer session and open dialogue where IGA developers are encouraged to provide their feedback.
There is no charge to attend the meeting; however, please note that CVM will be unable to provide refreshments or cover any travel-related costs for participants.
The Large Animal Genetic Engineering Summit will:
1. Provide updates on genetic engineering technologies, including genome editing, and their biomedical and agricultural applications in academia and industry.
2. Engage federal agencies, industry representatives and academic researchers in a policy development forum. The focus of this panel discussion will be to: broadly define large animal research areas/topics that include transgenesis; and develop joint strategies to improve funding focused on developing the best animal models for a given trait/disease (dual purpose with dual benefit and beyond).
Conference registration includes all sessions, printed proceedings, an opening reception, full breakfasts, refreshment breaks, and lunch on the first and last days.
The second day of the conference includes time in the afternoon to explore the Park City area. Enjoy the city’s shops, galleries and restaurants, use the local bike share service (with an electric motor boost), visit Utah State University’s Swaner EcoCenter and Preserve, see athletes training or experience a bobsled ride or ski jump yourself at the Utah Olympic Park which was the site of many events in the 2002 Winter Olympic Games.